Additional file 5 of Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study

  • Makito Miyake (作成者)
  • Kota Iida (作成者)
  • Nobutaka Nishimura (作成者)
  • Tatsuki Miyamoto (作成者)
  • Kiyohide Fujimoto (寄稿者)
  • Ryotaro Tomida (作成者)
  • Kazumasa Matsumoto (作成者)
  • Kazuyuki Numakura (作成者)
  • Junichi Inokuchi (作成者)
  • Shuichi Morizane (作成者)
  • Takahiro Yoneyama (作成者)
  • Yoshiaki Matsumura (作成者)
  • Takashige Abe (寄稿者)
  • Takeshi Yamada (作成者)
  • Naoki Terada (作成者)
  • Shuya Hirao (寄稿者)
  • Motohide Uemura (寄稿者)
  • Yuto Matsushita (寄稿者)
  • Rikiya Taoka (作成者)
  • Takashi Kobayashi (作成者)
  • Takahiro Kojima (作成者)
  • Yoshiyuki Matsui (作成者)
  • Hiroshi Kitamura (作成者)
  • Hiroyuki Nishiyama (作成者)
  • Masaharu Inoue (作成者)

データセット

説明

Additional file 5: Fig. S2. Landmark analysis of recurrence among patients treated with non-maintenance induction BCG (iBCG) or iBCG plus maintenance BCG (mBCG) at 24 months. Landmark RFS at 6, 12, and 18 months among patients treated with non-maintenance iBCG or iBCG plus mBCG are plotted and compared between matched groups A and B (left panel) and between matched groups B and C (right panel). The P values, hazard ratios (HRs), and 95% confidence intervals (CIs) are shown in the figures.
利用可能になった日2021
出版社figshare

データセットにアクセス

  • 1 学術論文

引用スタイル